CN104159887A - 酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途 - Google Patents

酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途 Download PDF

Info

Publication number
CN104159887A
CN104159887A CN201280063518.9A CN201280063518A CN104159887A CN 104159887 A CN104159887 A CN 104159887A CN 201280063518 A CN201280063518 A CN 201280063518A CN 104159887 A CN104159887 A CN 104159887A
Authority
CN
China
Prior art keywords
phenyl
compounds
och
compound
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280063518.9A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·尼内丝
A·马斯卡雷洛
R·A·尤尼斯
T·R·斯顿夫
P·C·莱亚尔
J·A·尤尼斯
C·佩雷拉·德·索萨·梅洛
R·R·卡内瓦罗洛
L·多梅内吉尼·基亚拉迪亚
A·博尔托利尼·西尔韦拉
A·B·A·拉兰热拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Santa Catarina
Original Assignee
Universidade Federal de Santa Catarina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Santa Catarina filed Critical Universidade Federal de Santa Catarina
Publication of CN104159887A publication Critical patent/CN104159887A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280063518.9A 2011-11-25 2012-11-26 酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途 Pending CN104159887A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BRPI1107312-8 2011-11-25
BRPI1107312-8A BRPI1107312B1 (pt) 2011-11-25 2011-11-25 Composto de acil-hidrazona
PCT/BR2012/000480 WO2013075199A1 (pt) 2011-11-25 2012-11-26 "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos

Publications (1)

Publication Number Publication Date
CN104159887A true CN104159887A (zh) 2014-11-19

Family

ID=48468927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280063518.9A Pending CN104159887A (zh) 2011-11-25 2012-11-26 酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途

Country Status (9)

Country Link
US (1) US20150191445A1 (enExample)
EP (1) EP2784061B1 (enExample)
JP (1) JP2015504432A (enExample)
KR (1) KR102189562B1 (enExample)
CN (1) CN104159887A (enExample)
BR (2) BRPI1107312B1 (enExample)
CA (1) CA2869807C (enExample)
RU (1) RU2664327C2 (enExample)
WO (1) WO2013075199A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110498809A (zh) * 2018-05-17 2019-11-26 香港科技大学深圳研究院 基于酰腙配体类的有机硼化合物及其制备方法和应用
CN113336729A (zh) * 2021-05-31 2021-09-03 四川大学华西医院 硝呋齐特类衍生物及其制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101719541B1 (ko) 2015-08-13 2017-03-24 연세대학교 산학협력단 항암용 약학 조성물 및 ano1 활성억제제
KR20170141542A (ko) * 2016-06-15 2017-12-26 국립암센터 위암을 예방 및 치료하는 rhoa 억제제의 약학적 조성물
KR102131331B1 (ko) 2018-09-19 2020-07-07 연세대학교 산학협력단 항암용 신규 약학 조성물 및 ano1 활성억제제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760021A (en) * 1983-11-14 1988-07-26 Director-General Of Agency Of Industrial Science & Technology Biological response modifier having cell differentiation-induction activity and process for production thereof
EP0400464A1 (en) * 1989-06-01 1990-12-05 Health Research, Inc. Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
CN1081909A (zh) * 1992-04-15 1994-02-16 安姆根有限公司 在减少副作用的条件下用干扰素治疗疾病的方法和制剂
CN1159324A (zh) * 1995-12-20 1997-09-17 日本脏器制药株式会社 活性氧、自由基去除剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
MXPA06007399A (es) 2003-12-23 2007-01-26 Gpc Biotech Inc Inhibidores de quinasas dependientes de ciclina, composiciones y usos relacionados con ellos.
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
RU2365589C2 (ru) * 2004-04-01 2009-08-27 Авентис Фармасьютикалз Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
CN1824657A (zh) * 2006-04-05 2006-08-30 贵州大学 3－取代－2－芳基取代－5－(3,4,5－三烷氧基苯基)－1,3,4－噁二唑衍生物及制备方法和用途
US20110189306A1 (en) * 2010-01-13 2011-08-04 Norbert Kartner COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760021A (en) * 1983-11-14 1988-07-26 Director-General Of Agency Of Industrial Science & Technology Biological response modifier having cell differentiation-induction activity and process for production thereof
EP0400464A1 (en) * 1989-06-01 1990-12-05 Health Research, Inc. Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
CN1081909A (zh) * 1992-04-15 1994-02-16 安姆根有限公司 在减少副作用的条件下用干扰素治疗疾病的方法和制剂
CN1159324A (zh) * 1995-12-20 1997-09-17 日本脏器制药株式会社 活性氧、自由基去除剂

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DEISE M.BORCHHARDT等: "Biochemical Evaluation of a Series of Synthetic Chalcone and Hydrazide Derivatives as Novel Inhibitors of Cruzain from Trypanosoma cruzi", 《J.BRAZ.CHEM.SOC.》 *
LAUREN LEE等: "Design, Synthesis, and Biological Evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
LINHONG JIN等: "Synthesis, structure, and bioactivity of N´-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
LINHONG JIN等: "Synthesis, structure, and bioactivity of N´-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 16, 31 December 2006 (2006-12-31), pages 5037 - 1 *
MAZZONE,G.;ARRIGO REINA,R.: "3,4,5-Trimethoxybenzoyl hydrazides and their anti-MAO [monoamine oxidase] activity", 《BOLLETTINO DELLE SEDUTE DELLA ACCADEMIA GIOENIA DI SCIENZE NATURALI IN CATANIA》 *
MAZZONE,G.等: "2,5-diaryl-substituted 1,3,4-oxadiazoles: synthesis and preliminary pharmacological research", 《FARMACO》 *
SHEHATA,I.A.等: "Synthesis and biological testing of certain 1,3,4-oxadiazole and 1,2,4-triazole derivatives as potential antimicrobial agents", 《SCIENTIA PHARMACEUTICA》 *
THAÍS MOREIRA OSÓRIO等: "Antibacterial activity of chalcones, hydrazones and oxadiazoles against methicillin-resistant Staphylococcus aureus", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
XIU-FANG CAO等: "Synthesis and Biological Activity of a Series of Novel N-Substituted β-Lactams Derived from Natural Gallic Acid", 《JOURNAL OF THE CHINESE CHEMICAL SOCIETY》 *
ZHAO WANG等: "Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening", 《J.CHEM.INF.MODEL.》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110498809A (zh) * 2018-05-17 2019-11-26 香港科技大学深圳研究院 基于酰腙配体类的有机硼化合物及其制备方法和应用
CN110498809B (zh) * 2018-05-17 2022-04-05 香港科技大学深圳研究院 基于酰腙配体类的有机硼化合物及其制备方法和应用
CN113336729A (zh) * 2021-05-31 2021-09-03 四川大学华西医院 硝呋齐特类衍生物及其制备方法和用途
CN113336729B (zh) * 2021-05-31 2022-05-27 四川大学华西医院 硝呋齐特类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
WO2013075199A1 (pt) 2013-05-30
BRPI1107312B1 (pt) 2021-09-08
CA2869807C (en) 2021-03-09
JP2015504432A (ja) 2015-02-12
CA2869807A1 (en) 2013-05-30
KR102189562B1 (ko) 2020-12-14
KR20140112489A (ko) 2014-09-23
EP2784061A4 (en) 2015-05-27
EP2784061A1 (en) 2014-10-01
EP2784061B1 (en) 2018-11-07
BR112014012582A2 (pt) 2017-06-06
RU2664327C2 (ru) 2018-08-16
US20150191445A1 (en) 2015-07-09
RU2014125519A (ru) 2015-12-27
BRPI1107312A2 (pt) 2016-09-20

Similar Documents

Publication Publication Date Title
JP4989976B2 (ja) 翻訳開始阻害剤としての３−３−二置換オキシインドール
EP2784061B1 (en) Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof
CN110002987A (zh) 苯基亚烯丙基环己烯酮衍生物及制备方法和用途
WO2018068665A1 (zh) 微管蛋白抑制剂
CN114315754A (zh) 一种异羟肟酸类化合物及其用途
CN108191770A (zh) 2,3-二氮杂萘酮或2,3-二氮杂萘酚衍生物及其用途
Madrigal-Angulo et al. Design, synthesis, biological and in silico evaluation of 3‑carboxy‑coumarin sulfonamides as potential antiproliferative agents targeting HDAC6
EP3252039B1 (en) Compound containing indoleacetic acid core structure and use thereof
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
Xing et al. Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers
CN110156822A (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
CN102688234A (zh) 吲哚酮衍生物作为rsk2抑制剂的合成与应用
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
CN102532118B (zh) 含有吲哚酮的4-噻唑烷酮类衍生物及其应用
WO2004039797A1 (en) A special kind of indole compounds, their preparation, and their use in treatment and prevention of those disease such as cancer
CN101684115B (zh) 4-(5-((2-(4-吗啉基-6-苯氨基-1,3,5-三嗪-2-基)亚肼基)甲基)呋喃-2-基)苯甲酸、其制备方法及用途
CN115057856B (zh) 3,5-二取代-7氮杂吲哚衍生物及其合成方法与应用
CN104177312B (zh) 一种含硒化合物及其医药用途
CN107098906A (zh) 苄基鸟嘌呤衍生物及其有机盐类化合物和药物组合物及其应用
CN103298344B (zh) 整链蛋白偶联性激酶抑制剂
CN115819349B (zh) 一种吡唑类化合物及其制备方法和应用
CN111153817B (zh) 苯氧基-n-苯基苯胺衍生物及其应用
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
CN107056707B (zh) 一种3,4,5-三甲氧基苯类化合物及其在制备抗氧化药物中的应用
CN102688233B (zh) 苯并三氮唑衍生物做为rsk2抑制剂的合成及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141119